-
The FDA has approved a combination product of amlodipine and atrovastatin for the treatment of patients with comorbid hypertension and hypercholesterolemia.
-
Although regular aspirin use reduces the risk for colorectal adenoma formation as shown in previous randomized-controlled trials, the protective effect now seems to be greatest at substantially higher doses (> 14 standard tablets/week) than currently recommended for cardiovascular prophylaxis.
-
B-type natriuretic peptide (BNP) is a biomarker released by cardiac ventricular myocytes. Its usefulness is mainly in the emergency room for the evaluation of acute dyspnea, to evaluate for cardiac failure. BNP may have usefulness as a screening test for preclinical heart disease, for risk stratification and for guidance with therapy.
-
-
The NIH has halted the estrogen-alone wing of the Womens Health Initiative a year before its scheduled end.
-
Metabolic syndrome, but not obesity alone, was associated with a higher risk of cardiovascular events. The presence of MS in individuals with angiographic CAD at study entry substantially increased the likelihood of death and major adverse cardiovascular events.
-
SYNERGY: The superior yield of the new Strategy of Enoxaparin, Revascularization, and Glycoprotein IIb/IIIa Inhibitors trial was presented by Dr. Kenneth Mahaffey and colleagues; WATCH: The Warfarin and Antiplatelet Trial in Chronic Heart failure was presented by Barry Massie, MD, from San Francisco.
-
-
Positive Alendronate Data in Osteoporosis; NSAIDs For Myocardial Infarction; Four-Hour Window for CAP Patients; FDA Actions.
-
Over the past 50 years, our understanding of the acute respiratory distress syndrome (ARDS) has evolved, not only with respect to the pathophysiology of lung injury and hypoxemia, but also with the definition of this syndrome and its treatment. We still have a long way to go in our understanding about the variability in pulmonary gas exchange in patients with ARDS.
